Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL
CLL dosing escalating study; daily dosing schedule; PK/PD safety
B-Cell Chronic Lymphocytic Leukemia
DRUG: CNF2024 (BIIB021)
Safety and toxicity (maximum tolerated dose (MTD)), 4 week periods until MTD is reached|Pharmacokinetics, Dosing period|Pharmacodynamics, Dosing period
To determine clinical and hematological response, Study Duration|To determine the recommended Phase 2 dose, Study duration
Phase 1, open-label, accelerated-titration study designed to evaluate the effects of increasing doses of CNF2024 on safety, pharmacokinetics, pharmacodynamic markers, and hematological response